Stay updated on Pembrolizumab for Metastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page.

Latest updates to the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page
- Check4 days agoChange DetectedRevision labels updated: v3.4.3 added and v3.4.2 removed.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedThe update appears to be a minor version bump from v3.4.1 to v3.4.2 with no visible changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedSite revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedAdded a glossary to the page and updated QC-related labels, including 'Last Update Submitted that Met QC Criteria' and the revision note 'Revision: v3.4.0'; removed the older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and the previous revision 'Revision: v3.3.4'.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check83 days agoChange DetectedLocations section now lists Oregon as a study site, reflected in Revision: v3.3.3. The previous Oregon Locations and HHS Vulnerability Disclosure links were removed (v3.3.2).SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab for Metastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page.